Source link : https://www.newshealth.biz/health-news/revumenib-approved-for-kmt2a-translocation-leukemia/
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory acute leukemia with a KMT2A gene translocation in adult and pediatric patients 1 year or older. The approval makes the oral small-molecule menin inhibitor the first pharmaceutical to carry the indication. It blocks the binding of menin to […]
Author : News Health
Publish date : 2024-11-18 12:34:10
Copyright for syndicated content belongs to the linked Source.
inHealth